Exscientia Will Expand Its Work With Amazon Web Services Using The Cloud Provider's Artificial Intelligence And Machine Learning Services To Power Its Platform For End-To-End Drug Discovery And Automation

7/10/24 7:18:09 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $EXAI alert in real time by email

The platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia's ability to deliver high quality drug candidates at faster speed and lower cost.

Get the next $EXAI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EXAI

Date	Price Target	Rating	Analyst
7/9/2024		Buy	TD Cowen
1/5/2024	$11.00 → $9.00	Buy → Neutral	BofA Securities

More analyst ratings

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to commence in late 2024/early 2025 Exscientia plc (NASDAQ:EXAI) today announced it has reached an agreement to acquire GT Apeiron's share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property. The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of '617 in advanced solid tumours. R
7/18/24 7:00:00 AM ET
$EXAI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Exscientia Business Update for First Quarter 2024
Positive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into clinic in 2H24 and early 2025, respectively AI-design integration enhanced with full experiment automation driving towards maximum speed, quality and autonomous drug design Leveraging technology advancements and streamlining operations to realise annualised savings of $40 million Exscientia plc (NASDAQ:EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below. Exscient
5/21/24 7:00:00 AM ET
$EXAI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024
Company to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (NASDAQ:EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company's website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 (800) 358 0970 (U.K.), +1 (646) 960 0857 (International)
5/14/24 7:00:00 AM ET
$EXAI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone
8/8/24 7:39:25 AM ET
$EXAI
$RXRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology
— AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology drug development expertise to execute robust clinical strategy on Exscientia's internal oncology pipeline — Exscientia plc (NASDAQ:EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development. Appointed to Chief Technology Officer, John P. Overington, Ph.D.,
6/6/24 7:00:00 AM ET
$EXAI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Parker Moss to Join Exscientia as EVP, Corporate Development
Renowned technology champion to strengthen company's development of precision medicine and clinical innovation platforms Exscientia plc (NASDAQ:EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024. In this newly established role, Parker will lead the creation and execution of a focused corporate development strategy to strengthen further and create new market opportunities for the company's precision medicine, clinical and tech innovation platforms, with a particular focus on oncology. Reporting to CEO Andrew Hopkins, he will help the company's Executive Leadership Team to identify and shape new business opportuni
10/17/23 7:00:00 AM ET
$EXAI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$EXAI
Press Releases

Fastest customizable press release news feed in the world

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discoveryRecursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and Youtube SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (NASDAQ:RXRX) and Exscientia has been completed, wi
11/20/24 7:00:00 AM ET
$EXAI
$RXRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Recursion and Exscientia Shareholders Approve the Proposed Combination
Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) and Exscientia plc (NASDAQ:EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia. The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET / 5:30 a.m MT / 12:30 p.m. GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts. Questions can be submitted via this link ahead of
11/13/24 9:08:19 AM ET
$EXAI
$RXRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
Both programmes demonstrate Exscientia's ability to design highly differentiated, potentially best-in-class molecules Exscientia will receive $15 million for achieving these milestones and is eligible for over $600 million in additional milestone payments for these two programmes as well as high-single-digit to mid-teen royalties Three programmes in the partnership have now advanced through initial milestones with multiple more progressing at earlier stages Exscientia plc (NASDAQ:EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds
10/16/24 7:00:00 AM ET
$EXAI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Exscientia Will Expand Its Work With Amazon Web Services Using The Cloud Provider's Artificial Intelligence And Machine Learning Services To Power Its Platform For End-To-End Drug Discovery And Automation

Chat with this insight

Recent Analyst Ratings for
$EXAI

$EXAI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

TD Cowen initiated coverage on Exscientia plc

Exscientia plc downgraded by BofA Securities with a new price target

$EXAI
SEC Filings

SEC Form 15-12G filed by Exscientia Plc

SEC Form S-8 POS filed by Exscientia Plc

SEC Form S-8 POS filed by Exscientia Plc

$EXAI
Financials

Live finance-specific insights

$EXAI
Leadership Updates

Live Leadership Updates

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

Exscientia Business Update for First Quarter 2024

Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Parker Moss to Join Exscientia as EVP, Corporate Development

$EXAI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Exscientia Plc

Amendment: SEC Form SC 13D/A filed by Exscientia Plc

SEC Form SC 13G/A filed by Exscientia Plc (Amendment)

$EXAI
Press Releases

Fastest customizable press release news feed in the world

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion and Exscientia Shareholders Approve the Proposed Combination

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

Exscientia Will Expand Its Work With Amazon Web Services Using The Cloud Provider's Artificial Intelligence And Machine Learning Services To Power Its Platform For End-To-End Drug Discovery And Automation

Chat with this insight

Recent Analyst Ratings for $EXAI

$EXAI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

TD Cowen initiated coverage on Exscientia plc

Exscientia plc downgraded by BofA Securities with a new price target

$EXAI SEC Filings

SEC Form 15-12G filed by Exscientia Plc

SEC Form S-8 POS filed by Exscientia Plc

SEC Form S-8 POS filed by Exscientia Plc

$EXAI Financials

Live finance-specific insights

$EXAI Leadership Updates

Live Leadership Updates

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

Exscientia Business Update for First Quarter 2024

Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Parker Moss to Join Exscientia as EVP, Corporate Development

$EXAI Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Exscientia Plc

Amendment: SEC Form SC 13D/A filed by Exscientia Plc

SEC Form SC 13G/A filed by Exscientia Plc (Amendment)

$EXAI Press Releases

Fastest customizable press release news feed in the world

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion and Exscientia Shareholders Approve the Proposed Combination

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

Recent Analyst Ratings for
$EXAI

$EXAI
Analyst Ratings

$EXAI
SEC Filings

$EXAI
Financials

$EXAI
Leadership Updates

$EXAI
Large Ownership Changes

$EXAI
Press Releases